Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

Open access

Abstract

BACKGROUND: The anti-human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced disease eventually progress. Pertuzumab, an anti-HER2 humanized monoclonal antibody that inhibits receptor dimerization, has a mechanism of action that is complementary to that of trastuzumab, and combination therapy with the two antibodies has shown promising activity and an acceptable safety profile in phase 2 studies involving patients with HER2-positive breast cancer. METHODS: We randomly assigned 808 patients with HER2-positive metastatic breast cancer to receive placebo plus trastuzumab plus docetaxel (control group) or pertuzumab plus trastuzumab plus docetaxel (pertuzumab group) as first-line treatment until the time of disease progression or the development of toxic effects that could not be effectively managed. The primary end point was independently assessed progression-free survival. Secondary end points included overall survival, progression-free survival as assessed by the investigator, the objective response rate, and safety. RESULTS: The median progression-free survival was 12.4 months in the control group, as compared with 18.5 months in the pertuzumab group (hazard ratio for progression or death, 0.62; 95% confidence interval, 0.51 to 0.75; P<0.001). The interim analysis of overall survival showed a strong trend in favor of pertuzumab plus trastuzumab plus docetaxel. The safety profile was generally similar in the two groups, with no increase in left ventricular systolic dysfunction; the rates of febrile neutropenia and diarrhea of grade 3 or above were higher in the pertuzumab group than in the control group. CONCLUSIONS: The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT00567190.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1113216

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 2

  1. Molina MA, 2001, Cancer Res, 61, 4744
  2. Soltoff SP, 1994, Mol Cell Biol, 14, 3550, 10.1128/MCB.14.6.3550 · doi:10.1128/mcb.14.6.3550 · Paper page

Cited by

See all 2,532

Metadata

Authors
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., Clark, E., Benyunes, M. C., Ross, G., & Swain, S. M.
Affiliations
  • Vall d'Hebron Institute of Oncology (ES)
  • Asan Medical Center (KR)
  • Seoul National University (KR)
  • Universidade de São Paulo (BR)
  • Samsung Medical Center (KR)
  • Leningrad Regional Cancer Center (RU)
  • Grupo Hospitalar Conceição (BR)
  • Roche (United Kingdom) (GB)
  • Genentech (US)
  • MedStar Washington Hospital Center (US)
Venue
New England Journal of Medicine
Published
2012-01-12
Volume
366
Issue
2
Pages
109-119
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2166199281
Cited by
2,532
References
29
Citations by year
2026: 88 · 2025: 111 · 2024: 118 · 2023: 131 · 2022: 138 · 2021: 173 · 2020: 155 · 2019: 152 · 2018: 154 · 2017: 196 · 2016: 183 · 2015: 228 · 2014: 257 · 2013: 286 · 2012: 156
FWCI
109.78
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • New England Journal of Medicine (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders
National Cancer Institute (P30CA008748)
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
pertuzumab, trastuzumab, docetaxel, HER2-positive breast cancer, metastatic breast cancer, first-line therapy, progression-free survival, overall survival, cardiotoxicity, febrile neutropenia, diarrhea
MeSH terms
Trastuzumab, Docetaxel, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Ventricular Dysfunction, Left, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Taxoids, Kaplan-Meier Estimate, Young Adult, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. https://app.cochat.ai/papers/10.1056/nejmoa1113216
The paper
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., Clark, E., Benyunes, M. C., Ross, G., & Swain, S. M. (2012). Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1113216

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.